NR3C2 and Hyperkalemia: Its distinct binding characteristics also make Finerenone effective in conditions where MR mutations might render steroidal antagonists less effective, highlighting its potential as a refined third-generation MRA that can better manage risks like hyperkalemia and hormone-related side effects in vulnerable populations [20].